Oncostellae participates at the BIO-Europe partnering event taking place on October 25-28, 2021 in a digital format.
The company is in conversations to outlicense their IBD asset OST-122 that is currently in a Phase 2a proof-of-concept study in patients with ulcerative colitis. OST-122 is an oral, gut-restricted JAK3/TYK2/ARK5 inhibitor for the local treatment of inflammatory diseases in the GI tract.
In a FIH Phase 1 trial in healthy volunteers, OST-122 was well tolerated at high doses (up to 1200 mg) and showed minimal compound levels in plasma and no changes in hematology and biochemistry parameters.
After reiterated safety concerns by the FDA over serious adverse events after treatment with tofacitinib and other systemic JAK inhibitors, OST-122 stands out as a non-systemic and therefore safer JAK inhibitor that shows a way forward for the field toward local treatments in the GI tract and potentially other organs such as lung, skin, hair (loss), eye etc.